iCEMIGE: Integration of CEll-morphometrics, MIcrobiome, and GEne biomarker signatures for risk stratification in breast cancers

Figure 3 iCEMIGE significantly outperforms cellular morphometric prognosis score, 15-microbe abundance prognosis score, and cellular morphometric prognosis score in prognosis prediction in the Cancer Genome Atlas breast cancer cohort. A: Kaplan-Meier overall survival (OS) curves for breast cancer (BC) patients are presented according to iCEMIGE score groups; B: ROC curves for 10-year OS prediction across different signature scores. C: Area under the curve (AUC) of 10-year OS prediction across different signature scores; D: Kaplan-Meier progress-free survival (PFS) curves for BC patients are presented according to iCEMIGE score groups; E: Receiver operating characteristic (ROC) curves for 10-year PFS prediction across different signature scores. F: AUC of 10-year PFS prediction across different signature scores. The Kaplan-Meier p-values were calculated by the log-rank test among the three groups. The P values for AUC were obtained from Kruskal-Wallis test.